Bausch & Lomb metipranolol HCl
No launch date or price has been set for the ophthalmic beta-blocker, which was approved Dec. 29. B&L plans to drop tradename used in the NDA, Betamet, and has not yet selected a new one. In the Jan. 1 "The Pink Sheet" (pp. 1 & 18), Pharmaquest, B&L's agent in preparing the NDA, was mistakenly identified as the metipranolol sponsor.
You may also be interested in...
Informa Pharma Intelligence congratulates the winners of the fifth annual awards.
Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage.
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.